Development of eosinophilic granulomatosis with poliangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: A case report

Omalizumab is a monoclonal anti-immunoglobulin E antibody used for the treatment of severe perennial allergic asthma. Previous reports have suggested that omalizumab treatment can be associated with the development of eosinophilic granulomatosis with poliangiitis (EGPA) (formerly known as Churg-Stra...

Full description

Saved in:
Bibliographic Details
Published in:International journal of immunopathology and pharmacology 2015-03, Vol.28 (1), p.134-137
Main Authors: Borekci, S, Aydin, O, Hatemi, G, Gemicioglu, B
Format: Article
Language:English
Subjects:
Aged
Brain Neoplasms - drug therapy
Churg-Strauss Syndrome - chemically induced
Churg-Strauss Syndrome - etiology
Female
Granulomatosis with Polyangiitis - chemically induced
Granulomatosis with Polyangiitis - etiology
Humans
Omalizumab - adverse effects
Omalizumab - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Omalizumab is a monoclonal anti-immunoglobulin E antibody used for the treatment of severe perennial allergic asthma. Previous reports have suggested that omalizumab treatment can be associated with the development of eosinophilic granulomatosis with poliangiitis (EGPA) (formerly known as Churg-Strauss syndrome) and an increased risk of malignancy. Long-term risks of omalizumab treatment are not very well defined. Here, we report the case of a 75-year-old woman with concurrent occurrence of EGPA and brain tumor after more than 7 years of omalizumab treatment. The possibility of EGPA should be borne in mind during long-term treatment with omalizumab. Despite the absence of definitive data, an association may also exist between the development of malignancy and omalizumab use.
ISSN:0394-6320
2058-7384
DOI:10.1177/0394632015572567